Aeglea BioTherapeutics
expected phase interim data will validate if half life and is within predicted range as | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
14 of 37
Related slides by other companies
D-Wave
Investor Day
January 2024
comparing statistics | D-Wave
ATAI
Investor Presentation
October 2022
trial design all subjects placebo day to day screening visit day to day in clinic treatment visit day and day follow up visit and visit primary at last patient anticipated to be dosed this week with total number of patients expected to be around topline results expected around year end randomized phase study is establish human proof of concept on track read out | ATAI
MoneyLion
Investor Day
December 2022
min day is the expected digital media consumption for | MoneyLion
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Mergers and Acquisitions
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io